Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olorinab Phase 2a in Crohn's Disease Pain
NCT03155945Phase 2Completed
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Jul 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olorinab in Crohn's disease (2 arms), sponsored by Arena Pharmaceuticals, Inc. Primary endpoint: Treatment-Emergent Adverse Events at 12 weeks. Started Jul 2017; status: completed.
02
Drugs
olorinab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03155945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03155945.